Physician profile
Gitanjli Channan
NPI 1336146570
$4,434.53
in general payments reported to CMS, 2019-2025
27 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,442 · 2020: $489 · 2022: $189 · 2023: $994 · 2024: $819 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,315.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,285.21 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $576.08 | 2019-2025 | Evenity, Otezla, Repatha |
| Abbvie INC. | $538.80 | 2023-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $453.94 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $361.98 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $194.72 | 2019-2025 | |
| Amarin Pharma, INC. | $174.96 | 2019-2020 | |
| Zimmer Biomet Holdings, INC. | $135.00 | 2024 | A&E Medical / Sternalock Xp Rigid Fixation System |
| Eisai INC. | $120.65 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $92.10 | 2019 | |
| Novo Nordisk INC | $65.49 | 2019-2020 | |
| Esperion Therapeutics, INC. | $63.23 | 2023-2024 | Nexletol |
| Exact Sciences Corporation | $53.34 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $32.77 | 2019-2020 | |
| Glaxosmithkline, LLC. | $30.71 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tms Neurohealth Centers INC. | $29.85 | 2025 | Tms Neurohealth Centers INC. |
| Intra-Sana Laboratories | $28.44 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Takeda Pharmaceuticals U.S.A., INC. | $28.24 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $28.21 | 2019 | |
| Sunovion Pharmaceuticals INC. | $24.17 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $23.83 | 2020 | |
| Agepha Pharma Fz LLC | $23.60 | 2024 | Lodoco |
| Upsher-Smith Laboratories LLC | $18.17 | 2020 | |
| Genentech USA, INC. | $15.51 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.02 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.98 | 2019 | |
| Alfasigma USA, INC. | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gitanjli Channan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.